Synonyms: compound 99 [PMID 25380412]
Compound class:
Synthetic organic
Comment: GLPG0974 is a lead clinical development candidate compound which acts as an antagonist of the free fatty acid receptor 2 (FFA2) [3]. FFA2 is a GPCR involved in the mediation of inflammatory responses.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Cerep.
ExpresSProfile - P1. Accessed on 08/06/2015. Modified on 08/06/2015. http://www.cerep.fr, http://www.cerep.fr/cerep/users/pages/catalog/profiles/DetailProfile.asp?profile=2117 |
2. Namour F, Galien R, Van Kaem T, Van der Aa A, Vanhoutte F, Beetens J, Van't Klooster G. (2016)
Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects. Br J Clin Pharmacol, 82 (1): 139-48. [PMID:26852904] |
3. Pizzonero M, Dupont S, Babel M, Beaumont S, Bienvenu N, Blanqué R, Cherel L, Christophe T, Crescenzi B, De Lemos E et al.. (2014)
Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic. J Med Chem, 57 (23): 10044-57. [PMID:25380412] |